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FertilityYoung women with polycystic ovary syndrome (PCOS) have a high risk of developing endometrial cancer (EC).
There is an urgent need for non-surgical prevention and treatment strategies for these patients who fail to
respond to progesterone treatment andwish to preserve their fertility. Recently, we have reported that the com-
bined treatmentwithmetformin and progesterone-based oral contraceptives has successfully reversed the early-
stage EC into normal endometria in addition to improvement of insulin resistance in women with PCOS. More
importantly, one of these treated women has successfully delivered a healthy newborn baby. However, before
such treatment can be recommended to the clinical practice, themolecular basis of metformin in the endometri-
um under physiological and pathological conditions must be elucidated.
© 2014 Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Polycystic ovary syndrome (PCOS), a worldwide health problem, is a
heterogeneous hormone-imbalance disorders [1,2] and occurs in
approximately 4%–18% of reproductive-aged women (approximately
12 to 45 years old), depending on the deﬁnition [3]. While the etiology
and clinical characteristics of PCOS have been well recognized [4], the
underlying molecular mechanisms are under active investigation.
Endometrial cancer (EC) is the most common life-threatening gyne-
cological malignancy [5], and young womenwith PCOS have a high risk
of developing EC [6,7]. It has been reported that women with PCOS and
endometrial hyperplasia have four times greater risk of developing EC
thanwomenwithout PCOS [8]. Epidemiological studies have implicated
steroid hormonal imbalance in the development of EC [9]. In humans,
continuous exposure of the endometrium to estrogens can lead to endo-
metrial overgrowth and hyperplasia [10], and progesterone acts as a
protective factor against estrogen-driven uterine cell growth and prolif-
eration [11]. Women with PCOS often present with an abnormal
menstrual cycle and anovulation that result in a persistent progesterone
deﬁciency [12]. Thus, the endometrium in women with PCOS tends to
remain in an estrogen dominant proliferative state due to the lack of
counterbalance by progesterone [5,13]. In the clinic, progesterone-
based oral contraceptives are used to inhibit endometrial hyper-
proliferation and improve menstrual dysfunction [14]. However,
approximately 30% of women with PCOS fail to respond to such treat-
ment [15]. This results in the development and progression of atypical
hyperplasia and further transformation to EC. Although EC can be46 31 7863512.
icle under the CC BY-NC-ND licensedetected at an early stage, surgery is currently the only truly effective
means of treating EC in women with PCOS who have progesterone
resistance [12]. Furthermore, surgical treatment may negatively affect
future fertility. Therefore, there is an urgent need for non-surgical
prevention and treatment strategies for young women with PCOS who
wish to preserve their fertility [16].
Insulin resistance and hyperinsulinemia appear to be one of major
contributors to the pathophysiology of PCOS in women [17]. For
example, it has been reported that 50%–70% of women with PCOS
exhibit insulin resistance [18]. It is well known that metformin (N,N-
dimethylbiguanide), an oral biguanide insulin-sensitizing drug, is used
as ﬁrst-line treatment for type 2 diabetes mellitus worldwide [19]. We
and other investigators have previously shown that the combinational
therapy of metformin and progesterone-based oral contraceptives
such as Diane-35 is sufﬁcient to not only change the insulin resistance
state but also reverse atypical endometrial hyperplasia in women with
PCOS who fail to respond to progesterone treatment and preserve
their fertility [20,21]. Multiple lines of evidence support that treatment
with metformin results in decreased incidence, progression, and even
cancer-related mortality of different human cancers [22,23] including
EC [24]. That brings us to the question: doesmetformin have a beneﬁcial
effect on the endometrium inwomenwith PCOS and EC? Very recently,
we have reported that the similar combined treatment is capable of
reversing the early-stage EC into normal endometria (Fig. 1 B to D) in
addition to improvement of insulin resistance in women with PCOS
[25].
In our early phase human study [25], womenwith PCOS and ECwere
co-treatedwithmetformin andDiane-35 for 6 months. After the combi-
nation treatment, all patients were requested to continuously measure(http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Fig. 1.Hypotheticalmodels ofmetformin actions inwomenwith PCOS and early-stage endometrial cancer. On the basis of the evidence accumulated in othermetformin-target tissues, we
propose that the systemic and/or local endometria actions ofmetformin (A) revert the endometrial cancer into normal endometrial cells inwomenwith PCOS and early-stage endometrial
cancer. Representative microscopic photomicrographs of early endometrial carcinoma (B, clinical stage 1a, grade 1), complex hyperplasia with atypia (C), complex hyperplasia (D), and
normal endometria (E) in women with PCOS and early-stage endometrial cancer before, during, and after co-treatment with metformin and Diane-35. Microscopic images stained with
hematoxylin and eosin. Scale bar: 100 μm.
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tion occurs. If we ﬁnd that the ovulation did not occur, the patients
would receive progesterone-based oral contraceptive therapy during
the secretary phase of their menstrual cycle to prevent the endometria
from becoming atypical hyperplasia again. In addition, B-ultrasound is
used for regular follow-up observations in these patients. Regarding
the nature of the disease [1,2], women with PCOS who have previous
EC and atypical hyperplasia often relapse if there is no follow-up treat-
ment. Therefore, if we observe any abnormal changes, for example, in
endometrial thickness or shape, the patients must be examined using
hysteroscopy. Because the purpose of combination treatmentwithmet-
formin and oral contraceptives in women with PCOS and EC is to
preserve their uterus for future pregnancy [25], it is best to help patients
obtain regulated ovulation and subsequent normal uterine pregnancy
as early as possible after co-treatment. The good news is that one of
these treated women has successfully delivered a healthy newborn
baby (our unpublished data). Altogether, our work has suggested that
such treatment not only improves various endocrine and metabolic
symptoms, but also preserves the fertility in women with PCOS and EC.
As clinicians, we notice that our preliminary reports [25] must be
carefully weighed and further research is certainly needed before co-
treatment with metformin and oral contraceptives can be recommend-
ed as routine clinical practice. Having said that, this raises the question
as to how a positive effect of metformin combined with oral contracep-
tives at the molecular level could inhibit the development of atypical
endometrial hyperplasia and EC, whether metformin individually af-
fects endometrial function in women with PCOS, and how our ﬁndings
affect treatment guidelines for PCOS women with and without insulin
resistance. It is important to await the full analysis of the complete ﬁnd-
ings before reaching deﬁnitive conclusions. In fact, we have started anew randomized trial with a larger sample size and longer follow-up
period. The cellular and molecular mechanisms behind the treatment
effect will also be further investigated in greater detail.
The primary function of metformin is to inhibit hepatic gluconeo-
genesis and decrease glucose production in the liver that causes
decreased circulating glucose and insulin levels, while it improves insu-
lin sensitivity and enhance glucose uptake and utilization in peripheral
tissues such as skeletal muscle and adipocytes [23]. However, the iden-
tiﬁedmechanism of anti-diabetic and anti-cancer actions formetformin
in women with PCOS and EC has remained largely unknown [17,26].
Organic cation transporters (OCTs) and multidrug/toxin extrusion pro-
teins (MATEs) are crucial for the cellular uptake and excretion of met-
formin. We reported that speciﬁc OCTs and MATEs were expressed in
the human endometrium [27]. Therefore, future studies are needed to
clarify whether metformin has direct and/or indirect effects on the
endometrium in women with PCOS and EC (Fig. 1A). Because clinical
and epidemiological investigations suggest that obesity and type 2 dia-
betes are strong risk factors for increased EC incidence and mortality
[28], understanding the effects of metformin in the endometrium will
take us one step closer to understanding the molecular mechanisms of
EC inhibition, and may be beneﬁcial in ﬁnding out ways to prevent
and treat the EC development and progression in women with PCOS
and/or obesity.
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